

Michael E Thase

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5460105/publications.pdf>

Version: 2024-02-01

251
papers

15,837
citations

36303

51
h-index

18647

119
g-index

262
all docs

262
docs citations

262
times ranked

12468
citing authors

#	ARTICLE	IF	CITATIONS
1	Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report. <i>American Journal of Psychiatry</i> , 2006, 163, 1905-1917.	7.2	4,241
2	Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. <i>Contemporary Clinical Trials</i> , 2004, 25, 119-142.	1.9	898
3	Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder. <i>Neuropsychopharmacology</i> , 2006, 31, 1841-1853.	5.4	572
4	Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. <i>American Journal of Psychiatry</i> , 2019, 176, 428-438.	7.2	557
5	Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression. <i>JAMA Psychiatry</i> , 2019, 76, 893.	11.0	472
6	Efficacy of Quetiapine Monotherapy in Bipolar I and II Depression. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 600-609.	1.4	455
7	Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression. <i>JAMA Psychiatry</i> , 2018, 75, 139.	11.0	451
8	If at First You Don't Succeed. <i>Drugs</i> , 2011, 71, 43-64.	10.9	382
9	Cognitive Therapy Versus Medication in Augmentation and Switch Strategies as Second-Step Treatments: A STAR*D Report. <i>American Journal of Psychiatry</i> , 2007, 164, 739-752.	7.2	297
10	Remission Rates Following Antidepressant Therapy With Bupropion or Selective Serotonin Reuptake Inhibitors. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 974-981.	2.2	262
11	Common and Dissociable Dysfunction of the Reward System in Bipolar and Unipolar Depression. <i>Neuropsychopharmacology</i> , 2015, 40, 2258-2268.	5.4	210
12	Aripiprazole Monotherapy in Nonpsychotic Bipolar I Depression. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 13-20.	1.4	203
13	Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study. <i>Journal of Psychiatric Research</i> , 2019, 111, 59-67.	3.1	197
14	Relative Antidepressant Efficacy of Venlafaxine and SSRIs: Sex-Age Interactions. <i>Journal of Women's Health</i> , 2005, 14, 609-616.	3.3	168
15	Title is missing!. <i>Cognitive Therapy and Research</i> , 1999, 23, 381-399.	1.9	151
16	Opioid Modulation With Buprenorphine/Samidorphan as Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomized Double-Blind Placebo-Controlled Trial. <i>American Journal of Psychiatry</i> , 2016, 173, 499-508.	7.2	151
17	Efficacy and Safety of Low-field Synchronized Transcranial Magnetic Stimulation (sTMS) for Treatment of Major Depression. <i>Brain Stimulation</i> , 2015, 8, 787-794.	1.6	145
18	Computer-Assisted Cognitive-Behavior Therapy for Depression. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	2.2	144

#	ARTICLE	IF	CITATIONS
19	Efficacy and Safety of Adjunctive Brexpiprazole 2 mg in Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2015, 76, 1224-1231.	2.2	137
20	Adjunctive Brexpiprazole 1 and 3 mg for Patients With Major Depressive Disorder Following Inadequate Response to Antidepressants. <i>Journal of Clinical Psychiatry</i> , 2015, 76, 1232-1240.	2.2	135
21	You Gotta Work at It. <i>Clinical Psychological Science</i> , 2014, 2, 455-471.	4.0	133
22	Depression and sleep: pathophysiology and treatment. <i>Dialogues in Clinical Neuroscience</i> , 2006, 8, 217-226.	3.7	129
23	A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults. <i>European Neuropsychopharmacology</i> , 2016, 26, 979-993.	0.7	123
24	Neural substrates of trait ruminations in depression.. <i>Journal of Abnormal Psychology</i> , 2014, 123, 35-48.	1.9	121
25	Treatment resistance in psychiatry: state of the art and new directions. <i>Molecular Psychiatry</i> , 2022, 27, 58-72.	7.9	117
26	Suicide and sleep: Is it a bad thing to be awake when reason sleeps?. <i>Sleep Medicine Reviews</i> , 2016, 29, 101-107.	8.5	112
27	Efficacy of Cognitive-Behavioral Therapy for Insomnia Combined With Antidepressant Pharmacotherapy in Patients With Comorbid Depression and Insomnia. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e1316-e1323.	2.2	106
28	Cardiovascular Profile of Duloxetine, a Dual Reuptake Inhibitor of Serotonin and Norepinephrine. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 132-140.	1.4	101
29	Efficacy of Duloxetine and Selective Serotonin Reuptake Inhibitors. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 672-676.	1.4	100
30	Guidelines for the recognition and management of mixed depression. <i>CNS Spectrums</i> , 2017, 22, 203-219.	1.2	97
31	Improving the Efficiency of Psychotherapy for Depression: Computer-Assisted Versus Standard CBT. <i>American Journal of Psychiatry</i> , 2018, 175, 242-250.	7.2	93
32	NATURAL HISTORY AND PREVENTATIVE TREATMENT OF RECURRENT MOOD DISORDERS. <i>Annual Review of Medicine</i> , 1999, 50, 453-468.	12.2	83
33	Correlates and consequences of chronic insomnia. <i>General Hospital Psychiatry</i> , 2005, 27, 100-112.	2.4	82
34	A Double-blind Comparison Between Bupropion XL and Venlafaxine XR. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 482-488.	1.4	80
35	Preventing Relapse and Recurrence of Depression: A Brief Review of Therapeutic Options. <i>CNS Spectrums</i> , 2006, 11, 12-21.	1.2	77
36	Patterns of Suicidality and Alcohol Use in Alcoholics with Major Depression. <i>Alcoholism: Clinical and Experimental Research</i> , 1996, 20, 1451-1455.	2.4	76

#	ARTICLE	IF	CITATIONS
37	Association of exercise with quality of life and mood symptoms in a comparative effectiveness study of bipolar disorder. <i>Journal of Affective Disorders</i> , 2013, 151, 722-727.	4.1	76
38	Bipolar Depression: Issues in Diagnosis and Treatment. <i>Harvard Review of Psychiatry</i> , 2005, 13, 257-271.	2.1	74
39	Management of Patients With Treatment-Resistant Depression. <i>Journal of Clinical Psychiatry</i> , 2008, 69, e08.	2.2	74
40	Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression. <i>International Clinical Psychopharmacology</i> , 2010, 25, 189-198.	1.7	70
41	Skills of Cognitive Therapy (SoCT): A new measure of patients' comprehension and use.. <i>Psychological Assessment</i> , 2011, 23, 578-586.	1.5	70
42	Peripheral vascular endothelial growth factor as a novel depression biomarker: A meta-analysis. <i>Psychoneuroendocrinology</i> , 2015, 62, 18-26.	2.7	70
43	The Risk of Treatment-Emergent Mania With Methylphenidate in Bipolar Disorder. <i>American Journal of Psychiatry</i> , 2017, 174, 341-348.	7.2	68
44	Assessing the "true" effect of active antidepressant therapy <i>v.</i> placebo in major depressive disorder: use of a mixture model. <i>British Journal of Psychiatry</i> , 2011, 199, 501-507.	2.8	65
45	A Breathing-Based Meditation Intervention for Patients With Major Depressive Disorder Following Inadequate Response to Antidepressants. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e59-e63.	2.2	64
46	The assessment of resistance to antidepressant treatment: Rationale for the Antidepressant Treatment History Form: Short Form (ATHF-SF). <i>Journal of Psychiatric Research</i> , 2019, 113, 125-136.	3.1	64
47	Poor quality of life and functioning in bipolar disorder. <i>International Journal of Bipolar Disorders</i> , 2017, 5, 10.	2.2	63
48	Therapeutic Alternatives for Difficult-to-Treat Depression: A Narrative Review of the State of the Evidence. <i>CNS Spectrums</i> , 2004, 9, 808-821.	1.2	61
49	Adherence and Persistence Across Antidepressant Therapeutic Classes: A Retrospective Claims Analysis Among Insured US Patients with Major Depressive Disorder (MDD). <i>CNS Drugs</i> , 2017, 31, 421-432.	5.9	61
50	An Integrated Analysis of the Efficacy of Desvenlafaxine Compared with Placebo in Patients with Major Depressive Disorder. <i>CNS Spectrums</i> , 2009, 14, 144-154.	1.2	60
51	Modafinil Augmentation of SSRI Therapy in Patients with Major Depressive Disorder and Excessive Sleepiness and Fatigue: <i>A 12-Week, Open-label, Extension Study</i>. <i>CNS Spectrums</i> , 2006, 11, 93-102.	1.2	55
52	The Natural History of Insomnia: the incidence of acute insomnia and subsequent progression to chronic insomnia or recovery in good sleeper subjects. <i>Sleep</i> , 2020, 43, .	1.1	55
53	Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder. <i>JAMA - Journal of the American Medical Association</i> , 2022, 328, 151.	7.4	55
54	Treatment with Venlafaxine Extended Release After SSRI Nonresponse or Intolerance. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 250-258.	1.4	52

#	ARTICLE	IF	CITATIONS
55	Computer-assisted cognitive-behavior therapy for depression.. Psychotherapy, 2014, 51, 191-197.	1.2	51
56	STEP-BD and bipolar depression: What have we learned?. Current Psychiatry Reports, 2007, 9, 497-503.	4.5	50
57	Divergent relationship of depression severity to social reward responses among patients with bipolar versus unipolar depression. Psychiatry Research - Neuroimaging, 2016, 254, 18-25.	1.8	49
58	Using biomarkers to predict treatment response in major depressive disorder: evidence from past and present studies. Dialogues in Clinical Neuroscience, 2014, 16, 539-544.	3.7	48
59	Convergence in patient-therapist therapeutic alliance ratings and its relation to outcome in chronic depression treatment. Psychotherapy Research, 2017, 27, 410-424.	1.8	47
60	Treatment-Resistant Depression. Journal of Clinical Psychiatry, 2011, 72, e18.	2.2	47
61	Impact of Pharmacogenomics on Clinical Outcomes for Patients Taking Medications With Gene-Drug Interactions in a Randomized Controlled Trial. Journal of Clinical Psychiatry, 2019, 80, .	2.2	45
62	Are SNRIs more effective than SSRIs? A review of the current state of the controversy. Psychopharmacology Bulletin, 2008, 41, 58-85.	0.0	45
63	The role of homework in cognitive behavior therapy of depression.. Journal of Psychotherapy Integration, 2006, 16, 162-177.	1.1	43
64	The cardiovascular safety profile of escitalopram. European Neuropsychopharmacology, 2013, 23, 1391-1400.	0.7	43
65	The promise of cognitive behavior therapy for treatment of severe mental disorders: a review of recent developments. World Psychiatry, 2014, 13, 244-250.	10.4	43
66	Bipolar depression: Diagnostic and treatment considerations. Development and Psychopathology, 2006, 18, 1213-30.	2.3	39
67	Improving Cost-effectiveness and Access to Cognitive Behavior Therapy for Depression: Providing Remote-Ready, Computer-Assisted Psychotherapy in Times of Crisis and Beyond. Psychotherapy and Psychosomatics, 2020, 89, 307-313.	8.8	39
68	Examining the Efficacy of Adjunctive Aripiprazole in Major Depressive Disorder. Primary Care Companion To the Journal of Clinical Psychiatry, 2008, 10, 440-447.	0.6	39
69	A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, FIXED-DOSE PHASE III STUDY OF VILAZODONE IN PATIENTS WITH GENERALIZED ANXIETY DISORDER. Depression and Anxiety, 2015, 32, 451-459.	4.1	38
70	Computer-Assisted Cognitive-Behavior Therapy for Depression in Primary Care. primary care companion for CNS disorders, The, 2018, 20, .	0.6	38
71	Efficacy of vilazodone on anxiety symptoms in patients with major depressive disorder. International Clinical Psychopharmacology, 2014, 29, 351-356.	1.7	37
72	Improving Depression Outcome by Patient-Centered Medical Management. American Journal of Psychiatry, 2018, 175, 1187-1198.	7.2	37

#	ARTICLE	IF	CITATIONS
73	Durability of treatment response to zolpidem with three different maintenance regimens: a preliminary study. <i>Sleep Medicine</i> , 2015, 16, 1160-1168.	1.6	36
74	Olanzapine/Fluoxetine Combination in Patients With Treatment-Resistant Depression. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 451-462.	2.2	36
75	OnabotulinumtoxinA for the treatment of major depressive disorder: a phase 2 randomized, double-blind, placebo-controlled trial in adult females. <i>International Clinical Psychopharmacology</i> , 2020, 35, 19-28.	1.7	35
76	Pharmacotherapy of bipolar depression: An update. <i>Current Psychiatry Reports</i> , 2006, 8, 478-488.	4.5	34
77	THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY SURVEY OF PSYCHOPHARMACOLOGISTS'S PRACTICE PATTERNS FOR THE TREATMENT OF MOOD DISORDERS. <i>Depression and Anxiety</i> , 2015, 32, 605-613.	4.1	34
78	Clinical research challenges posed by difficult-to-treat depression. <i>Psychological Medicine</i> , 2022, 52, 419-432.	4.5	34
79	The next step forward: a move toward evidence, and away from fear of the industry. <i>Psychopharmacology Bulletin</i> , 2002, 36, 4-5.	0.0	34
80	A Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Sustained-Release Bupropion on Blood Pressure in Individuals With Mild Untreated Hypertension. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 302-307.	1.4	33
81	EXTENDED RELEASE QUETIAPINE FUMARATE IN MAJOR DEPRESSIVE DISORDER: ANALYSIS IN PATIENTS WITH ANXIOUS DEPRESSION. <i>Depression and Anxiety</i> , 2012, 29, 574-586.	4.1	32
82	A clinical measure of suicidal ideation, suicidal behavior, and associated symptoms in bipolar disorder: Psychometric properties of the Concise Health Risk Tracking Self-Report (CHRT-SR). <i>Journal of Psychiatric Research</i> , 2015, 71, 126-133.	3.1	32
83	Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 330-348.	2.6	32
84	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin in Patients With Major Depressive Disorder and an Inadequate Response to Therapy (CLARITY). <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	2.2	32
85	A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don't work well enough?. <i>World Journal of Biological Psychiatry</i> , 2021, 22, 483-494.	2.6	32
86	Psychotherapy Alone and Combined With Medication as Treatments for Bipolar II Depression. <i>Journal of Clinical Psychiatry</i> , 2018, 79, 7-15.	2.2	31
87	Primary care and mental health providers' perceptions of implementation of pharmacogenetics testing for depression prescribing. <i>BMC Psychiatry</i> , 2020, 20, 518.	2.6	29
88	Side Effects to Antidepressant Treatment in Patients With Depression and Comorbid Panic Disorder. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 433-440.	2.2	29
89	Quetiapine monotherapy in bipolar II depression: combined data from four large, randomized studies. <i>International Journal of Bipolar Disorders</i> , 2013, 1, 10.	2.2	28
90	Treatment of anxiety disorders with venlafaxine XR. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 269-282.	2.8	27

#	ARTICLE	IF	CITATIONS
91	Aripiprazole in bipolar depression: a pooled, post-hoc analysis by severity of core depressive symptoms. <i>International Journal of Psychiatry in Clinical Practice</i> , 2012, 16, 121-131.	2.4	27
92	Complex polypharmacy in bipolar disorder: Side effect burden, adherence, and response predictors. <i>Journal of Affective Disorders</i> , 2019, 257, 17-22.	4.1	26
93	Depressive symptoms carry an increased risk for suicidal ideation and behavior in bipolar disorder without any additional contribution of mixed symptoms. <i>Journal of Affective Disorders</i> , 2019, 246, 775-782.	4.1	26
94	Is academic psychiatry for sale?. <i>British Journal of Psychiatry</i> , 2003, 182, 388-390.	2.8	25
95	CBT MobileWork®: User-Centered Development and Testing of a Mobile Mental Health Application for Depression. <i>Cognitive Therapy and Research</i> , 2021, 45, 287-302.	1.9	25
96	Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder. <i>European Neuropsychopharmacology</i> , 2017, 27, 773-781.	0.7	24
97	Evaluating antidepressant therapies: remission as the optimal outcome. <i>Journal of Clinical Psychiatry</i> , 2003, 64 Suppl 13, 18-25.	2.2	24
98	Comparing venlafaxine extended release and fluoxetine for preventing the recurrence of major depression: Results from the PREVENT study. <i>Journal of Psychiatric Research</i> , 2011, 45, 412-420.	3.1	22
99	A tool to predict suicidal ideation and behavior in bipolar disorder: The Concise Health Risk Tracking Self-Report. <i>Journal of Affective Disorders</i> , 2016, 192, 212-218.	4.1	22
100	White blood cell count correlates with mood symptom severity and specific mood symptoms in bipolar disorder. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 355-365.	2.3	22
101	Efficacy and Safety of Seltorexant as Adjunctive Therapy in Major Depressive Disorder: A Phase 2b, Randomized, Placebo-Controlled, Adaptive Dose-Finding Study. <i>International Journal of Neuropsychopharmacology</i> , 2021, 24, 965-976.	2.1	22
102	Update on Partial Response in Depression. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 4-9.	2.2	22
103	Detecting Sudden Gains during Treatment of Major Depressive Disorder: Cautions from a Monte Carlo Analysis. <i>Current Psychiatry Reviews</i> , 2015, 11, 19-31.	0.9	21
104	Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 1928-36.	2.2	21
105	Circadian Preference as a Moderator of Depression Outcome Following Cognitive Behavioral Therapy for Insomnia Plus Antidepressant Medications: A Report From the TRIAD Study. <i>Journal of Clinical Sleep Medicine</i> , 2019, 15, 573-580.	2.6	20
106	The Neglected Role of Psychotherapy for Treatment-Resistant Depression. <i>American Journal of Psychiatry</i> , 2022, 179, 90-93.	7.2	20
107	Defined symptom-change trajectories during acute-phase cognitive therapy for depression predict better longitudinal outcomes. <i>Behaviour Research and Therapy</i> , 2016, 87, 48-57.	3.1	19
108	Clinical correlates of acute bipolar depressive episode with psychosis. <i>Journal of Affective Disorders</i> , 2017, 217, 29-33.	4.1	19

#	ARTICLE	IF	CITATIONS
109	Recognition and diagnosis of atypical depression. <i>Journal of Clinical Psychiatry</i> , 2007, 68 Suppl 8, 11-6.	2.2	19
110	Dysfunctional Attitudes, Attributional Styles, and Phase of Illness in Bipolar Disorder. <i>Cognitive Therapy and Research</i> , 2010, 34, 24-34.	1.9	18
111	Effect of adjunctive benzodiazepines on clinical outcomes in lithium- or quetiapine-treated outpatients with bipolar I or II disorder: Results from the Bipolar CHOICE trial. <i>Journal of Affective Disorders</i> , 2014, 161, 30-35.	4.1	18
112	Stable remission and recovery after acute-phase cognitive therapy for recurrent major depressive disorder.. <i>Journal of Consulting and Clinical Psychology</i> , 2014, 82, 1049-1059.	2.0	18
113	Predictors of longitudinal outcomes after unstable response to acute-phase cognitive therapy for major depressive disorder.. <i>Psychotherapy</i> , 2015, 52, 268-277.	1.2	18
114	Trajectories of suicidal ideation over 6 months among 482 outpatients with bipolar disorder. <i>Journal of Affective Disorders</i> , 2017, 223, 146-152.	4.1	18
115	Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder. <i>International Journal of Neuropsychopharmacology</i> , 2017, 20, 613-618.	2.1	18
116	Sleep disturbance may impact treatment outcome in bipolar disorder: A preliminary investigation in the context of a large comparative effectiveness trial. <i>Journal of Affective Disorders</i> , 2018, 225, 563-568.	4.1	18
117	Comparing sensitivity to change using the 6-item versus the 17-item Hamilton depression rating scale in the GUIDED randomized controlled trial. <i>BMC Psychiatry</i> , 2019, 19, 420.	2.6	18
118	Combinatorial Pharmacogenomic Algorithm is Predictive of Citalopram and Escitalopram Metabolism in Patients with Major Depressive Disorder. <i>Psychiatry Research</i> , 2020, 290, 113017.	3.3	18
119	Achieving remission and managing relapse in depression. <i>Journal of Clinical Psychiatry</i> , 2003, 64 Suppl 18, 3-7.	2.2	18
120	Tricyclics and newer antidepressant medications: Treatment options for treatment-resistant depressions. <i>Depression</i> , 1994, 2, 152-168.	0.6	17
121	Do antidepressants really work? A clinicians'™ guide to evaluating the evidence. <i>Current Psychiatry Reports</i> , 2008, 10, 487-494.	4.5	17
122	Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: post hoc analyses of three placebo-controlled studies. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 37-45.	2.2	17
123	Treatment of bipolar depression: current status, continued challenges, and the STEP-BD approach. <i>Psychiatric Clinics of North America</i> , 2003, 26, 495-518.	1.3	16
124	A Propensity Score Analysis of Homework Adherence-Outcome Relations in Cognitive Behavioral Therapy for Depression. <i>Behavior Therapy</i> , 2019, 50, 285-299.	2.4	16
125	Is sleep disturbance linked to short- and long-term outcomes following treatments for recurrent depression?. <i>Journal of Affective Disorders</i> , 2020, 262, 323-332.	4.1	16
126	Remission as the critical outcome of depression treatment. <i>Psychopharmacology Bulletin</i> , 2002, 36, 12-25.	0.0	16

#	ARTICLE	IF	CITATIONS
127	The Small Specific Effects of Antidepressants in Clinical Trials: What Do They Mean to Psychiatrists?. <i>Current Psychiatry Reports</i> , 2011, 13, 476-482.	4.5	15
128	The effect of personalized guideline-concordant treatment on quality of life and functional impairment in bipolar disorder. <i>Journal of Affective Disorders</i> , 2014, 169, 144-148.	4.1	15
129	Recommendations for Screening for Depression in Adults. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 349.	7.4	15
130	HIV Prevalence Among Hospitalized Patients at the Main Psychiatric Referral Hospital in Botswana. <i>AIDS and Behavior</i> , 2018, 22, 1503-1516.	2.7	15
131	Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder. <i>Neuropsychopharmacology</i> , 2019, 44, 2268-2276.	5.4	15
132	Improvement in self-reported quality of life with cognitive therapy for recurrent major depressive disorder. <i>Journal of Affective Disorders</i> , 2014, 167, 37-43.	4.1	14
133	Group (‘‘Project Life Force’’) versus individual suicide safety planning: A randomized clinical trial. <i>Contemporary Clinical Trials Communications</i> , 2020, 17, 100520.	1.1	14
134	Cariprazine Augmentation to Antidepressant Therapy in Major Depressive Disorder: Results of a Randomized, Double-Blind, Placebo-Controlled Trial. <i>Psychopharmacology Bulletin</i> , 2018, 48, 62-80.	0.0	14
135	Effects of levomilnacipran extended-release on motivation/energy and functioning in adults with major depressive disorder. <i>International Clinical Psychopharmacology</i> , 2016, 31, 332-340.	1.7	13
136	Longitudinal social-interpersonal functioning among higher-risk responders to acute-phase cognitive therapy for recurrent major depressive disorder. <i>Journal of Affective Disorders</i> , 2016, 199, 148-156.	4.1	13
137	Bipolar depression and suicidal ideation: Moderators and mediators of a complex relationship. <i>Journal of Affective Disorders</i> , 2019, 259, 164-172.	4.1	13
138	Insomnia Symptoms and Suicide-Related Ideation in U.S. Army Service Members. <i>Behavioral Sleep Medicine</i> , 2020, 18, 820-836.	2.1	13
139	Combinatorial Pharmacogenomic Testing Improves Outcomes for Older Adults With Depression. <i>American Journal of Geriatric Psychiatry</i> , 2020, 28, 933-945.	1.2	13
140	Adverse Effects of Second-Generation Antipsychotics as Adjuncts to Antidepressants. <i>Psychiatric Clinics of North America</i> , 2016, 39, 477-486.	1.3	12
141	Nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol do not affect 6-month mood-stabilizing treatment outcome among 482 patients with bipolar disorder. <i>Depression and Anxiety</i> , 2017, 34, 281-290.	4.1	12
142	Efficacy and safety of brexpiprazole as adjunctive treatment in major depressive disorder: overview of four short-term studies. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1907-1916.	1.8	12
143	Response to SSRI intervention and amygdala activity during self-referential processing in major depressive disorder. <i>NeuroImage: Clinical</i> , 2020, 28, 102388.	2.7	12
144	Antidepressant Combinations: Cutting Edge Psychopharmacology or Passing Fad?. <i>Current Psychiatry Reports</i> , 2013, 15, 403.	4.5	11

#	ARTICLE	IF	CITATIONS
145	Quantifying and qualifying the preventive effects of acute-phase cognitive therapy: Pathways to personalizing care.. Journal of Consulting and Clinical Psychology, 2016, 84, 365-376.	2.0	11
146	A meta-analysis of the efficacy of venlafaxine extended release 75â€“225â€“mg/day for the treatment of major depressive disorder. Current Medical Research and Opinion, 2017, 33, 317-326.	1.9	11
147	Comorbid anxiety in bipolar CHOICE: Insights from the bipolar inventory of symptoms scale. Journal of Affective Disorders, 2019, 246, 126-131.	4.1	11
148	The effect of esketamine in patients with treatmentâ€“resistant depression with and without comorbid anxiety symptoms or disorder. Depression and Anxiety, 2021, 38, 1120-1130.	4.1	11
149	A Review of Vilazodone, Serotonin, and Major Depressive Disorder. primary care companion for CNS disorders, The, 2014, 16, .	0.6	11
150	Augmentation Strategies for Depression: History and Concepts. CNS Spectrums, 2007, 12, 3-5.	1.2	10
151	Barriers to Cognitive Behavioral Therapy Homework Completion Scaleâ€“Depression Version: Development and Psychometric Evaluation. International Journal of Cognitive Therapy, 2012, 5, 219-235.	2.2	10
152	Critical appraisal of selegiline transdermal system for major depressive disorder. Expert Opinion on Drug Delivery, 2016, 13, 659-665.	5.0	10
153	Bipolar mixed features â€“ Results from the comparative effectiveness for bipolar disorder (Bipolar) Tj ETQq1 1 0.784314 rgBT /Overlo	4.1	10
154	Effects of vilazodone on suicidal ideation and behavior in adults with major depressive disorder or generalized anxiety disorder. International Clinical Psychopharmacology, 2017, 32, 281-288.	1.7	10
155	Clinically relevant and simple immune system measure is related to symptom burden in bipolar disorder. Acta Neuropsychiatrica, 2018, 30, 297-305.	2.1	10
156	Do comorbid social and other anxiety disorders predict outcomes during and after cognitive therapy for depression?. Journal of Affective Disorders, 2019, 242, 150-158.	4.1	10
157	Evaluation of MADRS severity thresholds in patients with bipolar depression. Journal of Affective Disorders, 2021, 286, 58-63.	4.1	10
158	Maintenance Therapy for Bipolar Disorder. Journal of Clinical Psychiatry, 2008, 69, e32.	2.2	10
159	MAOIs and Depression Treatment Guidelines. Journal of Clinical Psychiatry, 2012, 73, e24.	2.2	10
160	Social Skills Training for Depression and Comparative Efficacy Research: A 30-Year Retrospective. Behavior Modification, 2012, 36, 545-557.	1.6	9
161	A novel application of the <i>Intent to Attend</i> assessment to reduce bias due to missing data in a randomized controlled clinical trial. Clinical Trials, 2014, 11, 494-502.	1.6	9
162	An exploratory study of responses to low-dose lithium in African Americans and Hispanics. Journal of Affective Disorders, 2015, 178, 224-228.	4.1	9

#	ARTICLE	IF	CITATIONS
163	Initial Steps to inform selection of continuation cognitive therapy or fluoxetine for higher risk responders to cognitive therapy for recurrent major depressive disorder. <i>Psychiatry Research</i> , 2017, 253, 174-181.	3.3	9
164	Symptoms of Major Depressive Disorder Scale: Performance of a Novel Patient-Reported Symptom Measure. <i>Value in Health</i> , 2019, 22, 906-915.	0.3	9
165	Effect of pimavanserin on anxious depression in patients with major depression and an inadequate response to previous therapy: secondary analysis of the clarity study. <i>International Clinical Psychopharmacology</i> , 2020, 35, 313-321.	1.7	9
166	Improvement of sexual functioning during treatment of MDD with adjunctive pimavanserin: A secondary analysis. <i>Depression and Anxiety</i> , 2020, 37, 485-495.	4.1	9
167	Strategies for Increasing Treatment Adherence in Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2012, 73, e08.	2.2	9
168	Childhood trauma and treatment outcomes during mood-stabilising treatment with lithium or quetiapine among outpatients with bipolar disorder. <i>Acta Psychiatrica Scandinavica</i> , 2022, 145, 615-627.	4.5	9
169	Extreme Nonresponse to Acute Phase Cognitive Therapy for Depression: An Attempt to Replicate and Extend. <i>Behavior Therapy</i> , 2014, 45, 300-313.	2.4	8
170	Assessing cognitive therapy skills comprehension, acquisition, and use by means of an independent observer version of the Skills of Cognitive Therapy (SoCT-IO).. <i>Psychological Assessment</i> , 2016, 28, 205-213.	1.5	8
171	Clinical validation of combinatorial pharmacogenomic testing and single-gene guidelines in predicting psychotropic medication blood levels and clinical outcomes in patients with depression. <i>Psychiatry Research</i> , 2021, 296, 113649.	3.3	8
172	Remission With Venlafaxine Extended Release or Selective Serotonin Reuptake Inhibitors in Depressed Patients. <i>primary care companion for CNS disorders</i> , The, 2011, 13, .	0.6	8
173	On the propriety of collaborations between academicians and the pharmaceutical industry: an alternate viewpoint. <i>World Psychiatry</i> , 2007, 6, 29-31.	10.4	8
174	Effects of adjunctive brexpiprazole on calmness and life engagement in major depressive disorder: post hoc analysis of patient-reported outcomes from clinical trial exit interviews. <i>Journal of Patient-Reported Outcomes</i> , 2021, 5, 128.	1.9	8
175	Risk for Partner Victimization and Marital Dissatisfaction Among Chronically Depressed Patients. <i>Journal of Family Violence</i> , 2012, 27, 75-85.	3.3	7
176	Quetiapine XR monotherapy in major depressive disorder. <i>International Clinical Psychopharmacology</i> , 2013, 28, 113-120.	1.7	7
177	Tracking medication changes to assess outcomes in comparative effectiveness research: A bipolar CHOICE study. <i>Journal of Affective Disorders</i> , 2016, 205, 159-164.	4.1	7
178	Relapse prevention in adults with major depressive disorder treated with vilazodone. <i>International Clinical Psychopharmacology</i> , 2018, 33, 304-311.	1.7	7
179	The natural history of insomnia: Does sleep extension differentiate between those that do and do not develop chronic insomnia?. <i>Journal of Sleep Research</i> , 2021, 30, e13342.	3.2	7
180	Familial severe psychiatric history in bipolar disorder and correlation with disease severity and treatment response. <i>Journal of Affective Disorders</i> , 2020, 273, 131-137.	4.1	7

#	ARTICLE	IF	CITATIONS
181	Newer Medications for Complicated Depression. <i>Journal of Clinical Psychiatry</i> , 2009, 70, e33.	2.2	7
182	Quality of life after response to acute-phase cognitive therapy for recurrent depression. <i>Journal of Affective Disorders</i> , 2021, 278, 218-225.	4.1	6
183	Using Mechanism of Action to Choose Medications for Treatment-Resistant Depression. <i>Journal of Clinical Psychiatry</i> , 2015, 76, e1147-e1147.	2.2	6
184	Effect of Adjunctive Pimavanserin on Sleep/Wakefulness in Patients With Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2020, 82, .	2.2	6
185	Treating Major Depression: Antidepressant Algorithms. <i>Journal of Clinical Psychiatry</i> , 2009, 70, e46.	2.2	6
186	Patient Response Trajectories in Major Depressive Disorder. <i>Psychopharmacology Bulletin</i> , 2020, 50, 8-28.	0.0	6
187	Cardiometabolic risk markers during mood-stabilizing treatment: Correlation with drug-specific effects, depressive symptoms and treatment response. <i>Journal of Affective Disorders</i> , 2022, 300, 41-49.	4.1	6
188	Can Cognitive Therapy Be Conducted by Computers?. <i>Current Behavioral Neuroscience Reports</i> , 2015, 2, 209-215.	1.3	5
189	Adjunctive Therapy With Second-Generation Antipsychotics: The New Standard for Treatment-Resistant Depression?. <i>Focus (American Psychiatric Publishing)</i> , 2016, 14, 180-183.	0.8	5
190	Measures of suicidality in phase 3 clinical trials of levomilnacipran ER in adults with major depressive disorder. <i>CNS Spectrums</i> , 2017, 22, 475-483.	1.2	5
191	Relations of Shared and Unique Components of Personality and Psychosocial Functioning to Depressive Symptoms. <i>Journal of Personality Disorders</i> , 2018, 32, 577-602.	1.4	5
192	Patterns of changes in bipolar depressive symptoms revealed by trajectory analysis among 482 patients with bipolar disorder. <i>Bipolar Disorders</i> , 2018, 21, 350-360.	1.9	5
193	Adjunctive antidepressant treatment among 763 outpatients with bipolar disorder: Findings from the Bipolar CHOICE and LiTMUS trials. <i>Depression and Anxiety</i> , 2021, 38, 114-123.	4.1	5
194	Study design and implementation of the PRrecision Medicine In MEntal health Care (PRIME Care) Trial. <i>Contemporary Clinical Trials</i> , 2021, 101, 106247.	1.8	5
195	Bipolar Disorder Maintenance Treatment. <i>Journal of Clinical Psychiatry</i> , 2012, 73, e15.	2.2	5
196	The Role of Dyadic Discord in Outcomes in Acute Phase Cognitive Therapy for Adults With Recurrent Major Depressive Disorder. <i>Behavior Therapy</i> , 2019, 50, 778-790.	2.4	4
197	Effect of adjunctive pimavanserin on suicidal ideation in patients with major depression: Analysis of the CLARITY study. <i>Journal of Affective Disorders</i> , 2020, 277, 478-485.	4.1	4
198	Estimating outcome probabilities from early symptom changes in cognitive therapy for recurrent depression.. <i>Journal of Consulting and Clinical Psychology</i> , 2019, 87, 510-520.	2.0	4

#	ARTICLE	IF	CITATIONS
199	Using Adjunctive Treatments When First-Line Antidepressants Fail. <i>Journal of Clinical Psychiatry</i> , 2012, 73, e01.	2.2	4
200	The Failure of Evidence-Based Medicine to Guide Treatment of Antidepressant Nonresponders. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 1833-1835.	2.2	4
201	Combinatorial pharmacogenomic algorithm is predictive of sertraline metabolism in patients with major depressive disorder. <i>Psychiatry Research</i> , 2022, 308, 114354.	3.3	4
202	Treatment of Recurrent Depression. <i>CNS Drugs</i> , 2003, 17, 1119-1122.	5.9	3
203	Large-Scale Study Suggests Specific Indicators for Combined Cognitive Therapy and Pharmacotherapy in Major Depressive Disorder. <i>JAMA Psychiatry</i> , 2014, 71, 1101.	11.0	3
204	Decreased activation and subsyndromal manic symptoms predict lower remission rates in bipolar depression. <i>Australian and New Zealand Journal of Psychiatry</i> , 2018, 52, 994-1002.	2.3	3
205	Partner criticism during acute-phase cognitive therapy for recurrent major depressive disorder. <i>Behaviour Research and Therapy</i> , 2019, 113, 48-56.	3.1	3
206	Do patients' cognitive therapy skills predict personality change during treatment of depression?. <i>Behaviour Research and Therapy</i> , 2020, 133, 103695.	3.1	3
207	Cognitive and Behavioral Therapies. , 0, , 1920-1947.		3
208	Translating Clinical Science Into Effective Therapies. <i>Journal of Clinical Psychiatry</i> , 2014, 75, e11.	2.2	3
209	US Food and Drug Administration's Review of the Novel Antidepressant Vortioxetine. <i>Journal of Clinical Psychiatry</i> , 2015, 76, e120-e121.	2.2	3
210	Diagnosis and Treatment of a Major Depressive Episode. <i>Journal of Clinical Psychiatry</i> , 2009, 70, e37.	2.2	3
211	Lithium plus antipsychotics or anticonvulsants for bipolar disorder: Comparing clinical response and metabolic changes. <i>Australian and New Zealand Journal of Psychiatry</i> , 2023, 57, 93-103.	2.3	3
212	Correlation between white blood cell count and mood-stabilising treatment response in two bipolar disorder trials. <i>Acta Neuropsychiatrica</i> , 2019, 31, 230-234.	2.1	2
213	Could Treatment Matching Patients' Beliefs About Depression Improve Outcomes?. <i>Behavior Therapy</i> , 2019, 50, 765-777.	2.4	2
214	Prevalence of predicted gene-drug interactions for antidepressants in the treatment of major depressive disorder in the Precision Medicine in Mental Health Care Study. <i>Journal of Affective Disorders</i> , 2021, 282, 1272-1277.	4.1	2
215	Evaluation of MADRS Severity Thresholds in Patients With Bipolar Depression. <i>CNS Spectrums</i> , 2021, 26, 182-183.	1.2	2
216	Does Symptom Linkage Density Predict Outcomes in Cognitive Therapy for Recurrent Depression?. <i>Journal of Psychopathology and Behavioral Assessment</i> , 2022, 44, 469-480.	1.2	2

#	ARTICLE	IF	CITATIONS
217	Durability of treatment response to zolpidem using a partial reinforcement regimen: does this strategy require priming?. <i>Sleep Medicine</i> , 2021, 87, 56-61.	1.6	2
218	Improving Depression Outcome by Patient-Centered Medical Management. <i>Focus (American Psychiatric)</i> Tj ETQq0 0.0 rgBT /Qverlock 10	0.8	2
219	Managing Medical Comorbidities in Patients With Depression to Improve Overall Prognosis. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e1496-e1496.	2.2	2
220	Pharmacotherapeutic Treatment Strategies for Antidepressant Nonresponse. <i>Journal of Clinical Psychiatry</i> , 2009, 70, e42.	2.2	2
221	Evaluating Atypical Antipsychotics in the Treatment of Refractory Depression. <i>Journal of Clinical Psychiatry</i> , 2009, 70, e14.	2.2	2
222	Pharmacologic and therapeutic strategies in treatment-resistant depression. Augmentation strategies. <i>CNS Spectrums</i> , 2009, 14, 7-10.	1.2	2
223	Current and Emerging Treatments to Address Unmet Needs in MDD. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	2.2	2
224	Treatment of refractory bipolar depression. <i>Current Psychiatry Reports</i> , 2007, 9, 495-496.	4.5	1
225	49 Combinatorial Pharmacogenomics to Guide Treatment Selection for Major Depressive Disorder: A Large, Blinded, Randomized Controlled Trial. <i>CNS Spectrums</i> , 2019, 24, 202-203.	1.2	1
226	50 Adjunctive Buprenorphine/Samidorphan Combination in Patients with Major Depressive Disorder: Phase 3 Long-term Extension Study Results. <i>CNS Spectrums</i> , 2019, 24, 203-204.	1.2	1
227	M191. EFFECT OF BREXPIPIRAZOLE ON ENGAGEMENT IN PATIENTS WITH SCHIZOPHRENIA: POST-HOC ANALYSIS OF THREE STUDIES. <i>Schizophrenia Bulletin</i> , 2020, 46, S208-S209.	4.3	1
228	Charting Sea Changes in Outpatient Pharmacotherapy of Bipolar Disorder. <i>American Journal of Psychiatry</i> , 2020, 177, 651-653.	7.2	1
229	Strategies for Optimizing the Treatment of Major Depressive Disorder. , 2021, 70, S11-S19.		1
230	Healthcare Provider Perspectives on Bipolar I Disorder Screening and the Rapid Mood Screener (RMS), a Pragmatic, New Tool. <i>CNS Spectrums</i> , 2021, 26, 181-181.	1.2	1
231	Response and remission rates during 24 weeks of mood-stabilizing treatment for bipolar depression depending on early non-response. <i>Psychiatry Research</i> , 2021, 305, 114194.	3.3	1
232	Gauging the Use of Second-Generation Antipsychotics: Medicaid Benefits Data Suggest Much Room for Improvement. <i>Journal of Clinical Psychiatry</i> , 2018, 79, 17com11460.	2.2	1
233	Applying Antidepressant Study Results to Clinical Practice. <i>Journal of Clinical Psychiatry</i> , 2012, 73, e21.	2.2	1
234	Levels of depressed mood and low interest for two years after response to cognitive therapy for recurrent depression. <i>Behaviour Research and Therapy</i> , 2022, 148, 103996.	3.1	1

#	ARTICLE	IF	CITATIONS
235	Management commentary. , 0 , 278-281.		0
236	Therapeutic Armamentarium. , 0 , 861-875.		0
237	BOLDER II study of quetiapine therapy for bipolar depression. <i>Future Neurology</i> , 2007, 2, 373-377.	0.5	0
238	Does concomitant antidepressant therapy enhance response to electroconvulsive therapy?. <i>Current Psychiatry Reports</i> , 2009, 11, 423-425.	4.5	0
239	No evidence for switching antidepressants in treatment-resistant depressed patients. <i>Evidence-Based Medicine</i> , 2010, 15, 120-121.	0.6	0
240	Cognitive-behavioral therapy reduced risk for recurrence in patients recently hospitalized with cardiovascular disease events. <i>Annals of Internal Medicine</i> , 2011, 154, JC5.	3.9	0
241	Response to the letter entitled "Tachyphylaxis and Desensitization Depression" by Richard Skaff. <i>CNS Spectrums</i> , 2019, 26, 1-2.	1.2	0
242	181 A Phase-2 Sequential Parallel Comparison Design Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder. <i>CNS Spectrums</i> , 2020, 25, 314-315.	1.2	0
243	180 Improvement of Sexual Function Observed During Treatment of Major Depressive Disorder with Adjunctive Pimavanserin. <i>CNS Spectrums</i> , 2020, 25, 313-314.	1.2	0
244	Combinatorial Pharmacogenomic Testing Improves Outcomes for Older Adults With Depression. <i>Focus (American Psychiatric Publishing)</i> , 2021, 19, 76-85.	0.8	0
245	Safety of Using a Combinatorial Pharmacogenomic Test for Patients with Major Depressive Disorder in the GUIDED trial. <i>CNS Spectrums</i> , 2021, 26, 169-170.	1.2	0
246	Design of the national adaptive trial for PTSD-related insomnia (NAP study), VA cooperative study program (CSP) #2016. <i>Contemporary Clinical Trials</i> , 2021, 109, 106540.	1.8	0
247	The Role of Neurobiologic Processes in Treating Depression. <i>Journal of Clinical Psychiatry</i> , 2010, 71, e28.	2.2	0
248	The Role of Neurobiologic Processes in Symptoms of Depression. <i>Journal of Clinical Psychiatry</i> , 2011, 72, e08.	2.2	0
249	TREATMENT OF SEVERE DEPRESSION WITH COGNITIVE BEHAVIOR THERAPY. , 1994, , .		0
250	Introduction: the dual-action debate: does pharmacology matter?. <i>Journal of Clinical Psychiatry</i> , 2004, 65 Suppl 17, 3-4.	2.2	0
251	Obesogenic Medications and Weight Gain Over 24 Weeks in Patients with Depression: Results from the GUIDED Study. <i>Psychopharmacology Bulletin</i> , 2021, 51, 8-30.	0.0	0